Published in Biol Chem on July 01, 2009
Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer. Cancer Prev Res (Phila) (2010) 1.75
Tumor-infiltrating neutrophils in pancreatic neoplasia. Mod Pathol (2011) 1.14
Immunobiology of human mucin 1 in a preclinical ovarian tumor model. Oncogene (2012) 1.01
Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. Cancer Res (2010) 0.99
Design and synthesis of multifunctional gold nanoparticles bearing tumor-associated glycopeptide antigens as potential cancer vaccines. Bioconjug Chem (2012) 0.97
Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response. PLoS One (2012) 0.90
Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes. Bioconjug Chem (2013) 0.89
Loss of CD4 T-cell-dependent tolerance to proteins with modified amino acids. Proc Natl Acad Sci U S A (2011) 0.87
Tn glycosylation of the MUC6 protein modulates its immunogenicity and promotes the induction of Th17-biased T cell responses. J Biol Chem (2010) 0.86
MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge. Biomed Res Int (2012) 0.84
Characterization of an immunodominant cancer-specific O-glycopeptide epitope in murine podoplanin (OTS8). Glycoconj J (2010) 0.81
A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination. Oncotarget (2015) 0.79
Myeloid glycosylation defects lead to a spontaneous common variable immunodeficiency-like condition with associated hemolytic anemia and antilymphocyte autoimmunity. J Immunol (2014) 0.79
Antigen choice determines vaccine-induced generation of immunogenic versus tolerogenic dendritic cells that are marked by differential expression of pancreatic enzymes. J Immunol (2013) 0.77
MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice. PLoS One (2016) 0.77
Synthesis of a Liposomal MUC1 Glycopeptide-Based Immunotherapeutic and Evaluation of the Effect of l-Rhamnose Targeting on Cellular Immune Responses. Bioconjug Chem (2015) 0.76
Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer. Cancer Immunol Res (2016) 0.75
Induction of antigen-specific CTL and antibody responses in mice by a novel recombinant tandem repeat DNA vaccine targeting at mucin 1 of pancreatic cancer. J Cancer Res Clin Oncol (2010) 0.75
Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol (2005) 9.91
Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med (2001) 9.70
Two better cell lines for making hybridomas expressing specific T cell receptors. J Immunol (1989) 2.78
Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med (Berl) (1997) 2.21
Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev (2008) 2.07
Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes. J Immunol (2007) 2.05
HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res (2000) 1.86
Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res (1998) 1.59
Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology (2005) 1.50
Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res (1991) 1.41
Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol (1993) 1.37
Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother (2004) 1.36
Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology (2006) 1.35
Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proc Natl Acad Sci U S A (2006) 1.32
On the edge of autoimmunity: T-cell stimulation by steady-state dendritic cells prevents autoimmune diabetes. Diabetes (2005) 1.29
Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells. Cancer Res (2007) 1.26
Immature human dendritic cells express asialoglycoprotein receptor isoforms for efficient receptor-mediated endocytosis. J Immunol (2001) 1.24
A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther (2008) 1.22
The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J Immunol (2000) 1.21
A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res (1996) 1.17
The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. Cancer Immunol Immunother (2006) 1.14
Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res (2008) 1.11
Molecular cloning and characterization of a novel mouse macrophage C-type lectin, mMGL2, which has a distinct carbohydrate specificity from mMGL1. J Biol Chem (2002) 1.09
Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice. Vaccine (2003) 1.04
Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas. J Exp Med (2004) 1.00
Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells. J Immunol (2007) 0.98
CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. J Immunol (1998) 0.97
Glycoprotein tumor antigens for immunotherapy of breast cancer. Breast Dis (2004) 0.94
The cooperation between two CD4 T cells induces tumor protective immunity in MUC.1 transgenic mice. J Immunol (2005) 0.93
Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes. Mol Immunol (2008) 0.91
Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1. Blood (2008) 0.91
Nuclear magnetic resonance-based dissection of a glycosyltransferase specificity for the mucin MUC1 tandem repeat. Biochemistry (2003) 0.90
MHC-restricted, glycopeptide-specific T cells show specificity for both carbohydrate and peptide residues. J Immunol (1999) 0.89
Tumor antigen-based immunotherapy and immunoprevention of cancer. Int Arch Allergy Immunol (2006) 0.82
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 6.83
Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev (2005) 2.43
Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res (2013) 2.15
MUC1 immunobiology: from discovery to clinical applications. Adv Immunol (2004) 1.79
Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer. Cancer Prev Res (Phila) (2010) 1.75
De novo generation of cationic antimicrobial peptides: influence of length and tryptophan substitution on antimicrobial activity. Antimicrob Agents Chemother (2005) 1.70
MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res (2008) 1.66
MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) (2012) 1.39
Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother (2004) 1.36
Immune response as a biomarker for cancer detection and a lot more. N Engl J Med (2005) 1.35
IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur J Immunol (2011) 1.32
Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications. Antimicrob Agents Chemother (2005) 1.27
T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res (2005) 1.24
Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res (2008) 1.23
A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther (2008) 1.22
The catalytic subunit of shiga-like toxin 1 interacts with ribosomal stalk proteins and is inhibited by their conserved C-terminal domain. J Mol Biol (2008) 1.21
A role for the protease-sensitive loop region of Shiga-like toxin 1 in the retrotranslocation of its A1 domain from the endoplasmic reticulum lumen. J Biol Chem (2005) 1.21
Cutting edge: transgenic expression of human MUC1 in IL-10-/- mice accelerates inflammatory bowel disease and progression to colon cancer. J Immunol (2007) 1.21
Epidemiologic perspective on immune-surveillance in cancer. Curr Opin Immunol (2011) 1.16
Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev (2010) 1.15
Probing the impact of valency on the routing of arginine-rich peptides into eukaryotic cells. Biochemistry (2006) 1.12
Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.11
De novo-derived cationic antimicrobial peptide activity in a murine model of Pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother (2007) 1.10
Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J Immunol (2005) 1.09
Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies. Cancer Manag Res (2010) 1.08
Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53. Mol Immunol (2002) 1.07
MUC1 protein expression in tumor cells regulates transcription of proinflammatory cytokines by forming a complex with nuclear factor-κB p65 and binding to cytokine promoters: importance of extracellular domain. J Biol Chem (2011) 1.06
Inflammation driven by overexpression of the hypoglycosylated abnormal mucin 1 (MUC1) links inflammatory bowel disease and pancreatitis. Pancreas (2010) 1.05
Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis. Clin Exp Metastasis (2002) 1.03
A conditional mouse model for human MUC1-positive endometriosis shows the presence of anti-MUC1 antibodies and Foxp3+ regulatory T cells. Dis Model Mech (2009) 1.03
Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res (2006) 1.03
Mumps and ovarian cancer: modern interpretation of an historic association. Cancer Causes Control (2010) 1.03
Selective toxicity of engineered lentivirus lytic peptides in a CF airway cell model. Peptides (2003) 1.01
Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. Cancer Res (2010) 0.99
MUC1 immunotherapy is here to stay. Expert Opin Biol Ther (2012) 0.98
Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells. J Immunol (2007) 0.98
Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer Immunol Immunother (2011) 0.97
Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer. Proc Natl Acad Sci U S A (2009) 0.97
Charged and hydrophobic surfaces on the a chain of shiga-like toxin 1 recognize the C-terminal domain of ribosomal stalk proteins. PLoS One (2012) 0.94
Cancer vaccines: accomplishments and challenges. Crit Rev Oncol Hematol (2008) 0.94
Glycoprotein tumor antigens for immunotherapy of breast cancer. Breast Dis (2004) 0.94
A peptide-based dendrimer that enhances the splice-redirecting activity of PNA conjugates in cells. Bioconjug Chem (2009) 0.92
Altered glycosylation of MUC1 influences its association with CIN85: the role of this novel complex in cancer cell invasion and migration. Oncotarget (2013) 0.92
Incidence rate of breast cancer in young women. JAMA (2013) 0.91
Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes. Mol Immunol (2008) 0.91
Aberrant expression of MUC1 mucin in pediatric inflammatory bowel disease. Pediatr Dev Pathol (2010) 0.91
Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration. Immunology (2003) 0.90
Nuclear magnetic resonance-based dissection of a glycosyltransferase specificity for the mucin MUC1 tandem repeat. Biochemistry (2003) 0.90
Restraint stress and stress hormones significantly impact T lymphocyte migration and function through specific alterations of the actin cytoskeleton. Brain Behav Immun (2011) 0.89
Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals. Biochim Biophys Acta (2010) 0.89
The importance of valency in enhancing the import and cell routing potential of protein transduction domain-containing molecules. Biochim Biophys Acta (2005) 0.87
Cancer immunology. Curr Opin Immunol (2011) 0.87
A short DNA aptamer that recognizes TNFα and blocks its activity in vitro. ACS Chem Biol (2012) 0.87
Tandem dimerization of the human p53 tetramerization domain stabilizes a primary dimer intermediate and dramatically enhances its oligomeric stability. J Mol Biol (2006) 0.87
Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer. Mol Immunol (2009) 0.86
Lentivirus lytic peptide 1 perturbs both outer and inner membranes of Serratia marcescens. Antimicrob Agents Chemother (2002) 0.86
Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles. Cancer Immunol Immunother (2010) 0.86
Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulation. Semin Immunol (2010) 0.86
DNA vaccines for cancer too. Cancer Immunol Immunother (2005) 0.85
Construction and evaluation of the tumor imaging properties of 123I-labeled recombinant and enzymatically generated Fab fragments of the TAG-72 monoclonal antibody CC49. Bioconjug Chem (2007) 0.84
Human papillomavirus vaccine for cancer prevention. N Engl J Med (2009) 0.84
Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigen. Oncoimmunology (2012) 0.84
Cancer vaccines: a promising cancer therapy against all odds. Future Oncol (2007) 0.84
Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer. Ann N Y Acad Sci (2005) 0.83
Tumor antigens and tumor antigen discovery. Cancer Treat Res (2005) 0.83
Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms. Cancer Immunol Immunother (2012) 0.83
Tumor antigen-based immunotherapy and immunoprevention of cancer. Int Arch Allergy Immunol (2006) 0.82
Immunity against cyclin B1 tumor antigen delays development of spontaneous cyclin B1-positive tumors in p53 (-/-) mice. Ann N Y Acad Sci (2009) 0.82
AACR Cancer Progress Report 2012. Clin Cancer Res (2012) 0.82
A rapid and universal tandem-purification strategy for recombinant proteins. Protein Sci (2007) 0.80
Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8+ T cells by dendritic cells loaded with killed allogeneic breast cancer cells. Breast Cancer Res (2006) 0.80
Blocking the attachment of cancer cells in vivo with DNA aptamers displaying anti-adhesive properties against the carcinoembryonic antigen. Mol Oncol (2013) 0.80
An evolved ribosome-inactivating protein targets and kills human melanoma cells in vitro and in vivo. Mol Cancer (2010) 0.80
Lentiviral vectors encoding human MUC1-specific, MHC-unrestricted single-chain TCR and a fusion suicide gene: potential for universal and safe cancer immunotherapy. Cancer Immunol Immunother (2008) 0.79
Peptide- and polymer-based gene delivery vehicles. Methods Mol Med (2004) 0.79
Generation and immunosuppressive functions of p53-induced human adaptive regulatory T cells. Oncoimmunology (2013) 0.78
Designing peptide-based scaffolds as drug delivery vehicles. J Control Release (2002) 0.78
Tumor immunology at the service of cancer immunotherapy. Curr Opin Immunol (2004) 0.78
Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model. Cancer Immunol Immunother (2015) 0.78
A focused immune response targeting the homotypic binding domain of the carcinoembryonic antigen blocks the establishment of tumor foci in vivo. Int J Cancer (2012) 0.78
Mucins in gastrointestinal cancers. Cancer Chemother Biol Response Modif (2003) 0.78
Preventive immunization of aged and juvenile non-human primates to β-amyloid. J Neuroinflammation (2012) 0.77
Antigen choice determines vaccine-induced generation of immunogenic versus tolerogenic dendritic cells that are marked by differential expression of pancreatic enzymes. J Immunol (2013) 0.77
Fusion of the CH1 domain of IgG1 to epidermal growth factor (EGF) prolongs its retention in the blood but does not increase tumor uptake. Cancer Biother Radiopharm (2002) 0.77
In vivo generation of cytotoxic T cells from epitopes displayed on peptide-based delivery vehicles. J Immunol (2002) 0.77
Early in vivo signaling profiles in MUC1-specific CD4(+) T cells responding to two different MUC1-targeting vaccines in two different microenvironments. Oncoimmunology (2013) 0.77
Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas. Ann N Y Acad Sci (2013) 0.77
Folate receptor-targeted multimodality imaging of ovarian cancer in a novel syngeneic mouse model. Mol Pharm (2015) 0.77
Influenza virus infection elicits protective antibodies and T cells specific for host cell antigens also expressed as tumor-associated antigens: a new view of cancer immunosurveillance. Cancer Immunol Res (2013) 0.77
A stable human p53 heterotetramer based on constructive charge interactions within the tetramerization domain. J Biol Chem (2002) 0.76
Novel mechanisms underlying the immediate and transient global tolerization of splenic dendritic cells after vaccination with a self-antigen. J Immunol (2013) 0.76
Plasma microRNAs in ovarian cancer--response. Clin Cancer Res (2013) 0.75
Cloning and expression of human membrane-bound and soluble engineered T cell receptors for immunotherapy. J Biomed Biotechnol (2006) 0.75
Cancer vaccines: emphasis on pediatric cancers. Curr Pharm Des (2010) 0.75
The Pseudomonas aeruginosa exotoxin A translocation domain facilitates the routing of CPP-protein cargos to the cytosol of eukaryotic cells. J Control Release (2012) 0.75